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Abstract 
In vivo and in vitro studies have indicated that the anterior pituitary hormone prolactin (PRL) is an immunoregulator and 
functions in the development of the neonatal immune system. In this study, prolactin receptor (PRL-R) expression from birth to 
adulthood as well as the effect of milk ingestion on the PRL-R expression were examined in splenocytes and thymocytes of 
neonatal rats. Three approaches were taken to measure PRL-R expression: (i) polymerase chain reaction (RT-PCR); (ii) antibody 
to PRL-R and Western blotting; (iii) antibody to PRL-R and flow cytometry. RT-PCR analysis revealed the short and long form 
of PRL-R mRNA in both spleen and thymus at every age tested. However, the long form of PRL-R mRNA was always more 
abundant than that of the short form. In addition, antipeptide antibody against the long form of PRL-R recognized 84 and 42 
kD proteins in the spleen, but only the 84 kD protein in the thymus. A monoclonal antibody U6 recognized 38 and 40 kD proteins 
in both the spleen and thymus. Although the mRNA level of PRL-R was relatively low at birth and increased with age in both 
the spleen and thymus, the levels of protein bands detected with both antibodies correlated with development in the spleen; 
whereas the levels remained steady in the thymus. Therefore, we concluded that the expression of PRL-R at the protein level is 
developmentally regulated in the spleen but not in the thymus. Finally. milk ingestion in the first seven hours decreased the 
percentage of cells expressing cell surface PRL-R, suggesting that milk-borne PRL may have a direct effect on lymphocytes. 
Keywords: Milk: Neonatal Immunity; Prolactin; Prolactin Receptor: Splenocytes; Thymocytes 
1. Introduction 
A growing body of evidence indicates that the ante- 
rior pituitary hormone, prolactin (PRL), is an im- 
munomodulator. For example, both decreased anti- 
body production and depressed cell mediated immunity 
have been observed in hypophysectomized rats (Nagy 
and Berczi, 1978). Similarly, immunosuppression has 
been observed after the administration of bromo- 
criptine, which decreases the circulating levels of PRL 
to nonhypophysectomized rats. Administration of exo- 
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genous PRL to the rats restored these immune func- 
tions (Berczi et al., 1981; Nagy and Berczi, 1983) and 
resulted in an increase in ornithine decarboxylase activ- 
ity (ODC), expression of the c-myc proto-oncogene and 
DNA synthesis in both spleen and thymus (Russell and 
Larson 1985; Berczi et al. 1991). Moreover. Mukherjee 
et al. (1990); Viselli et al. (1991) showed a direct 
mitogenic effect of PRL in vitro on splenocytes and 
thymocytes from rats in certain hormonal states. 
Several studies have shown that PRL plays a role in 
the development of the immune system. For instance, 
neonatal mice treated with either an antiserum to PRL 
or with bromocriptine displayed an altered develop- 
mental pattern of T and B cells in the spleen and 
thymus. The percentage of splenocytes and thymocytes 
expressing the CD4 surface marker (helper T cell) was 
reduced (Russell et al., 1988). Grove et al. (1991) 
examined the effect of PRL-poor milk on the develop- 
ment of the neonatal immune response because rat milk 
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contains PRL and the concentration is highest in early 
lactation (McMurtry and Malven. 1974; Grosvenor et 
al.. 1976). Splenocytes and thymocytes from neonatal 
rats ingesting PRL-poor milk. showed an accelerated 
and increased response to mitogens as well as alter- 
ations in the expression of cell stage specific antigens. 
The response of lymphocytes to PRL implies the 
presence of cell surface prolactin receptors (PRL-R). 
Indeed, binding studies with “‘I-labeled PRL, and flow 
cytometric analysis with antibodies to PRL-R indicate 
that human T and B lymphocytes as well as many 
subsets of rat lymphocytes display cell surface PRL-R 
(Russell et al., 1985; Viselli and Mastro 1993). 
Two forms of PRL-R. short (292 amino acids) and 
long (598 amino acids), have been identified in several 
normal rat tissue including liver, ovary. thymus and 
spleen (Shirota et al., 1990: Ouhtit et al., 1993; Gunes et 
al. 1993; Tourdine et al., 1994). Only an intermediate 
form (393 amino acids) has been found in a rat T 
lymphoma cell line, Nb2 (Shiu et al., 1983). Because the 
receptor is encoded by a single gene. alternative splicing 
of a primary transcript is most likely responsible for 
these different forms (Kelly et al., 1993). 
In the rat, all three forms of PRL-R are identical in 
the extracellular and transmembrdne domains but differ 
at certain regions of the cytoplasmic domain (Kelly et 
al., 1993). Both the long and intermediate forms, but 
not the short form, of the PRL-R have been shown to 
transduce a PRL signal for the induction of a milk 
protein gene (Lesueur et al., 1990; Ali et al.. 1992; 
Lesueur et al., 1991). 
Because milk-borne PRL appears to play a role in 
lymphocyte function and in the development of the 
immune system. we examined the forms of PRL-R 
expression in rat spleen and thymus from birth to 
adulthood. In addition, we asked if milk-PRL ingestion 
affected PRL-R expression. We found that splenocytes 
and thymocytes expressed PRL-R at all the ages tested. 
The level of PRL-R protein in the thymus was at adult 
level at birth, whereas in splenocytes it was low at birth 
and increased with age. In addition, milk deprivation or 
ingestion during the first 7 h after birth affected the 
percentage of cells expressing cell surface PRL-R. 
2. Materials and methods 
2.1. Anirnuls 
SpragueeDawley rats or pregnant rats (Harlan Lab- 
oratories, Indianapolis, IN) were housed in a room 
maintained at 20&22”C on a 14 h light, 10 h dark 
schedule with free access to food and water. In most 
cases, pups were allowed to remain with their mother 
until they reached an appropriate age. For some exper- 
iments. four pups were sacrificed immediately after 
birth (0 h), four of them were kept with the mother and 
allowed to suckle for 7 h (plus milk), and four of them 
were kept for 7 h (minus milk) in Styrofoam cups 
layered with wood chips and floated in a 39°C water 
bath. 
Nb2 cells, rat T lymphoma cell line (Gout et al., 
1980) were cultured in Fisher’s medium as described by 
Tanaka et al. (1980). NOG-8 cells, which were cloned 
from a normal mouse mammary gland cell, were a 
generous gift from Dr. Barbara Vonderhaar (NIH). 
NOG-8 cells were maintained in DMEM medium sup- 
plemented with 5% fetal calf serum, 100 U/ml peni- 
cillin. 100 mg/ml streptomycin. Nb2 cells and NOG-8 
cells are known to contain PRL-R (Shiu et al.. 1983; 
Hynes et al., 1985) and were used as positive controls in 
this study. CTLL-2 cells were obtained from Central- 
ized Biological Laboratory (CBL), Pennsylvania State 
University. This cell line does not contain PRL-R (Gala 
and Shevach. 1993), so therefore, it served as a negative 
control. 
Pups were decapitated, the spleens and thymi re- 
moved, and placed in sterile saline. For pups older than 
2 days of age, each tissue was handled separately. For 
younger animals, the tissues of four pups were com- 
bined. Cells were isolated as described (Gunes et al., 
1993). Cell counts were performed with a hemacytome- 
ter and viability determined by trypan blue exclusion. 
Cell viability averaged 85% for splenocytes and 96% for 
thymocytes. 
Total cytoplasmic RNA was extracted from a range 
of 2 x IO’ to 1 x 10’ cells by either the guanidinium 
thiocyanate method of Chomczynski and Sacchi (1987) 
or by the Glass Max RNA Micro isolation kit (Chirg- 
win, 1979: Gibco BRL, Gaithersburg, MD). Isolated 
RNA pellets were suspended in ribonuclease free water 
and quantified by spectrophotometry. 
Primers were designed and prepared (Oligo Synthesis 
by the Biotechnology Institute, Pennsylvania State Uni- 
versity) in order to differentiate the mRNA of the long 
form of the PRL-R from the short form (Fig. 1). The 5’ 
primer, TACATCGTTGAGCCCAGAG (352%269), 
was taken from a region preceding the transmembrane 
region. The sequences for both forms are homologous 
(Boutin et al., 1988). The sequences of the long and 
short forms diverge in their cytoplasmic regions. The 
short form 3’ primer, AGTCTGCAGCTTCAGTAG 
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(927-944) (Boutin et al., 1988), was taken from the 
sequences of the final 30 amino acids of the short form. 
The long form 3’ primer, CTGTCATAGCTTC- 
CGTGA (1037-1054) (Shirota et al., 1990). is from 
sequences after the short form stops. The expected PCR 
products using these primers are 701 bp for the long 
form and 593 bp for the short form. Actin primers (5’ 
primer CACTGGCATTGTGATGGA; 3’ primer ACG- 
GATGTCAACGTCACA) were chosen from the se- 
quence of rat j?-actin gene (Nude1 et al., 1983) to 
produce a 427 bp PCR product. 
2.5. Preparation of F3 and actin probes 
A Bluescript plasmid containing the PRL-R short 
form (F3. a generous gift from Dr. Paul Kelly; Kelly et 
al., 1989) was cut with restriction enzymes NcoI and 
BamHl (Gibco-BRL, Gaithersbug, MD). This piece 
was purified by agarose gel electrophoresis and 
quantified by spectrophometry. Similarly, rat actin 
DNA was cut by EcoRl and Pst 1, and purified. Both 
were biotinylated using the polarplex chemiluminescent 
blotting kit (Millipore/New England Biolabs, Beverly, 
MA). Briefly, template DNA was denatured in boiling 
water for 5 min, cooled on ice for 5 min, and then 
centrifuged. A labelling mix containing random biotiny- 
lated octomers, a mix of dNTPs containing bio-dUTP, 
and DNA polymerase 1 (Klenow fragment) were added 
and incubated at 37°C for 1 h. The probe was stored at 
- 20°C until used. 
2.6. Reverse transcription and PCR ampkjication 
(RT-PCR) 
Total RNA (10 Fig) was reverse transcribed to cDNA 
with 200 U of M-MLV reverse transcriptase (Gibco 
BRL, Gaithersburg, MD) as described (Gunes et al., 
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Fig. 1. Peptide and primer design for antibody production and PCR 
of the long and short forms of PRL-R. 3’ primers were designed using 
nonhomologous sequences in order to differentiate the long and short 
form mRNA. For antibody production, amino acid sequences were 
chosen from non-homologous sequences to distinguish the short and 
long forms. 
1993). The cDNA was amplified using 2.5 U of taq 
polymerase (Perkin-Elmer, Norwalk, CT) in a thermo- 
cycler programmed with the following cycles: cycle 1, 3 
min at 94°C 2 min at 50°C. 2 min at 72°C; cycles 2-39, 
1 min at 94°C 1 min at 5O”C, 2 min at 72°C; and cycle 
40, 1 min at 94°C 1 min at 50°C. 10 min at 72°C. A 
sample without cDNA served as negative control. After 
amplification, PCR products were kept at - 20°C until 
used. 
2.7. Southern blot analysis 
The amplified cDNA was electrophoresed through a 
1.5% agarose gel containing 0.001% ethidium bromide 
and transferred to Immobilon-S membrane (Millipore, 
Beverly, MA). Prehybridization was performed for at 
least for 1 h at 68°C in a solution of 6 x SSC, 5 x 
Denhart’s reagent, 0.5% SDS, 10 mg/ml denatured 
salmon sperm DNA. 
Both PRL-R cDNA and actin cDNA were biotiny- 
lated using the polarplex chemiluminescent blotting kit. 
The biotinylated probe was added to a hybridization 
bag at a concentration of 20 ng/ml and kept overnight 
at 68°C. After hybridization, the membrane was pro- 
cessed for detection by the polarplex chemiluminescent 
kit. The membrane was exposed to XARS X-ray film 
for various lengths of time so that the resulting bands 
were within the linear range of the film. 
2.8. Quantification of PRL-R bands 
In order to compare the relative levels of the two 
forms of PRL-R, primers for actin, a house-keeping 
gene was included in the PCR reaction. The Southern 
blots were scanned by densitometry (Quick Scan Jr., 
Helena Laboratories, Beamont, TX). Quantitative anal- 
ysis of mRNA for PRL-R was carried out by normaliz- 
ing the densitometric signal for the short and long form 
with that of actin. Also PRL-Rs detected with Western 
blotting were quantified in similar fashion. 
2.9. Flow cytometric anulysis 
Staining with antibody to PRL-R and flow cytomet- 
ric analysis were carried out as described by Viselli et 
al. (1993). In brief, lymphocytes were plated at 1 x lo6 
cell/well in 96 well v-bottom plates. Primary antibody, 
a polyclonal anti-PRL-R to the extracellular egion of 
the receptor, a gift from Dr. Kurt Ebner (University of 
Kansas, Medical Center) and preimmune serum, which 
served as a negative control, were added at 1:100 
dilutions. Anti-leukocyte common antigen (LCA) was 
used at a 1: 1600 dilution. Incubation was carried out 
for 25 min at 4°C. Cells were washed twice with PBS 
(pH 7.5) containing 2% calf serum, 1% goat serum, and 
0.01% azide, and incubated with a 1:lOO dilution of 
phycoerythrin-conjugated secondary antibody for 25 
min at 4°C. Ten thousand cells were analyzed with flow 
cytometry. The fluorescence of phycoerythrin was mon- 
itored using an Epics 753 flow cytometer (Coulter 
Corp, Hialeah, FL). Laser excitation was 488 nm and 
the fluorescent signal was collected using a 456- 503 nm 
laser blocking filter, a 550 nm long pass dichroic filter 
to separate the PE signal, and with a 575 nm bandpass 
filter in front of the yellow photomultiplier tube. Per- 
centages were normalized to the percentage of cells 
bearing the LCA (96-98% thymus; 58 76% spleen). 
2.10. [-‘H]thvmidine incorporution 
Splenocytes were cultured at 2.5 x 10” cells:ml in 
triplicate in 200 ~1 volumes in 96-well flat bottom tissue 
culture plates. Thymocytes were cultured at 5 x 10” 
cells/ml in triplicate in a 200 /ll volume in 96-well 
round bottom tissue culture plates. Cells were incu- 
bated with ConA (1 ilg/rnl) for 72 h. In order to 
measure DNA synthesis, 0.5 ,~lCi [3H]TdR was added to 
each well at 48 h and 24 h later, cells were harvested 
onto glass fiber filter paper. [jH]TdR incorporation was 
measured by liquid scintillation spectroscopy as de- 
scribed (Mastro et al., 1991). 
2.1 I. Anti-peptide untibocly prodwtion 
In order to produce antibodies to the long form of 
PRL-R, a multiple antigen peptide (MAP) unique to 
the cytoplasmic region of the long form of PRL-R (Fig. 
1) was prepared by Research Genetics (Huntsville, AL). 
Injection of the synthetic peptide to rabbit and blood 
collection were carried out by CBL, Pennsylvania State 
University. IgG was purified with protein G column 
(Pierce) and kept either at - 20°C until used, or at 4°C 
in 0.01% sodium azide up to one month. We also used 
the same strategy to produce an anti-peptide antibody 
to the short form of the receptor but we were unsuc- 
cessful. However, we used a monoclonal antibody U6 
to PRL-R (a generous gift from Dr. Paul Kelly, IN- 
SERM, Paris, France) for comparison. 
2.12. Indirect ELISA to detrrnline urltibodJ$ titer 
Determination of the antibody titer in serum raised 
against a synthetic peptide was performed according to 
the method of Van Regenmortel (1988). 
2.13. Prepurution of’ liver nkrosomes und solubilizution 
of’ IJwlphocyte proteins 
Two adult virgin female Sprague-Dawley rats were 
injected subcutaneously with 17-p estradiol and bro- 
mocriptine as described by Katoh et al. (1987). Livers 
were removed and homogenized using a Polytron 
PTIO-35 (Brinkmann Instruments, Westburg, NY). Mi- 
crosomes were prepared (Katoh et al., 1987) in a buffer 
containing 2 mM PMSF and stored at - 20°C until 
used. 
Solubilization of membrane and cytoplasmic proteins 
of lymphocytes was carried out as described by Coligan 
et al. (1994). Briefly, cells were suspended at 2 x 10’ 
cells in 5 ml ice-cold PBS and centrifuged for 5 min at 
500 x ,y, 4°C. The pellet was resuspended in 200 ~1 
Triton X-100 lyses bufler (300 mM NaCl, 50 mM 
Tris-Cl pH 7.6. 0.5% Triton X-100) with protease in- 
hibitors. I mM PMSF, 10 Llg:‘rnl aprotinin, 10 /lg;rnl 
leupeptin and kept on ice for about 1 h. The samples 
were microcentrifuged for 15 min at 10 000 x g at 4°C. 
Supernatants were aliquoted at 50 ~11 and kept at 
~ 20°C until used. 
2. 14. Western blot mul~sis 
Solubilized membranes and cytosolic proteins were 
separated on 10% SDS-polyacrylamide gel elec- 
trophoresis (Laemmli, 1970) and electrophoretically 
transferred (150 mAmp, 1 h, 0.9 mAmp/cm’) to 
polyvinylidene difluoride (PVDF) membrane (Mil- 
lipore, Beverely, MA) using a graphite plate electroblot- 
ting apparatus (Andersen, 1984). Prestained molecular 
weight markers were both electrophoresed and electrob- 
lotted. The membrane was incubated with a mono- 
clonal antibody U6 to PRL-R or with a polyclonal 
antibody to the long form of PRL-R or with an anti- 
actin mAb (Oncogene Science, Uniondale, NY). 
Protein bands were detected with an enhanced chemilu- 
minescent (ECL) Western blotting kit (Amersham, Ar- 
lington Heights. IL). 
3. Results 
3.1. C’IlLlI.LI~.t~~ri-uti~)n cf pol~&nul untiboc!l, to the kwg 
f&w qf PRL-R 
ln order to test whether antibodies were produced 
against the injected synthetic peptide, indirect ELISA 
assays were carried out. The comparison of absorbance 
values for the rabbit antiserum with that of normal 
rabbit serum indicated that the rabbit had produced 
antibodies against the MAP peptide for the long form 
of PRL-R (Fig. 2). 
Because the MAP contains synthetic peptide and 
polylysine. microtiter plates for ELISA assays also were 
coated with an unrelated MAP peptide. However, the 
rabbit antiserum did not cross react with an unrelated 
MAP peptide (Fig. 2); almost the same absorbance 
values were obtained with antiserum and normal rabbit 
serum. 
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Fig. 2. Characterization of antibodies produced against he peptide of 
the long form of PRL-R using ELISA assay. The wells of a microtiter 
plate were coated with 100 ~1 of 1 pg/ml synthetic peptide for the 
long form of PRL-R; and serial dilutions of rabbit antiserum (l:lOO, 
1:500, l:lOOO, 1:5000, 1:lO 000) were added into triplicate wells (0). 
Normal rabbit serum served as a control (W). To test for possible 
cross reactivity of the antibody to the long form of PRL-R with an 
unrelated MAP peptide, the wells of microtiter plate were coated with 
the peptide for the short form and incubated with rabbit antiserum 
for the long form (0). After 1 h incubation at 37”C, the wells were 
washed and further incubated for 1 h with alkaline phosphatase 
conjugated goat anti rabbit second antibodies at 1:lOOO dilution. 
Wells were washed and color intensity after addition of the enzyme 
substrate (p-nitrophenylphosphate) was measured at 450 nm with a 
microtiter plate reader. The difference among the absorbance values 
of triplicate samples was less than 2%. 
In order to determine if the antipeptide antibodies 
recognized denatured PRL-Rs, liver microsomes were 
subjected to SDS-PAGE and Western blotting. Anti- 
body to the long form of PRL-R detected a protein 
with an estimated molecular weight (M,) of 84 kD (Fig. 
3(A), lanes 2-4). A monoclonal antibody to rat liver 
PRL-R (Okamura et al., 1989), U6, recognized two 
proteins (lane 1) with an approximate M, of 38 and 40 
kD lane 1). No proteins were detected with normal 
rabbit serum (lanes 5 and 6). 
In addition to liver microsomes, cell lysates from 
Nb2 cells, NOG-8 cells (a mouse mammary gland cell 
line) and splenocytes from ovariectomized rats were 
analyzed (Fig. 3(B)). Splenocyte lysate (lane 1) showed 
an 84 and 42 kD protein, Nb2 (lane 2) showed a 52 kD 
protein band, and NOG-8 (lanes 3-6) showed three 
proteins of 84, 53, and 42 kD. The antibody did not 
detect any proteins in lysates of CTLL-2 cells (a mouse 
IL-2 dependent cell line) which was used as a negative 
control because it does not express PRL-R (Gala and 
Stevach, 1993). Together these results indicated that the 
antibodies to the long form were specific for PRL-Rs. 
Further evidence that these proteins were PRL-R long 
form came from experiments done with lysates of 
mouse 3T3 cells transfected with the long form of the 
human PRL-R. The antipeptide antibodies revealed 
one large protein band at about 90 kD by Western 
blotting. However, these antibodies did not detect any 
protein in lysates of 3T3 cells transfected with the short 
form of the mouse PRL-R (Personal communication 
with Dr. Barbara Vonderhaar who tested our antibod- 
ies in her laboratory). 
3.2. Developmental expression of PRL-R at the protein 
level 
The antipeptide antibodies specific for the long form 
of the receptor were used to examine how PRL-R 
changed during neonatal development. Protein lysates 
from splenocytes or thymocytes of rats at birth (0 h) or 
1, 2, 8, 10, 14, 22, and 30 days were analyzed by 
Western blotting. Two protein bands with molecular 
mass of 42 and 84 kD were detected in splenocytes (Fig. 
4(A)). The 84 kD band was at a relatively low level 
from birth to 14 days of age (Fig. 4(B)). After day 14, 
it increased gradually for rats aged 22, 30, 40, and 50 
A 
Mrxio-3 
1231 
BQ- 
67- 
50- 
Fig. 3. Western blot analysis of PRL-R from rat liver microsome (A) 
and lysates of Nb2 cells, NOG-8 cells, CTLL-2 cells and splenocytes 
from ovariectomized rats (B). Crude liver microsome and cell lysates 
were subjected to 10% SDS-PAGE, transferred to PVDF membrane 
and incubated with different antibodies. (A) Lane 1 (200 fig micro- 
some) with U6 mAb (I:1000 dilution); lanes 2-4 (100, 200, 500 fig 
microsome) with antibodies to the long form of PRL-R (I:1000 
dilution); lanes 5 and 6 (200, 500 pg microsome) with normal rabbit 
serum (I : 1000 dilution). (B) 15 p I of each cell lysate (2 x 10’ cells in 
200 ~1 lysis buffer) was loaded in the first three lanes (1, splenocytes; 
2. Nb2; 3, NOG-8). Lanes 4-6 contained 10, 20, 30 ~1 of NOG-8 
lysate; lane 7, 20 ~1 of CTLL-2 lysate. Lanes 1-7 were incubated with 
antibodies to the long form of PRL-R (1:lOOO); Lane 8 (30 ~1 of 
NOG-8 lysate) with normal rabbit serum (1:lOOO). After incubation 
with horse radish peroxidase (MRP) conjugated-second antibody at 
1:4000 dilution, the protein bands were detected using ECL. 
A A 
1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 1011 
-ACTIN 
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Days After Birth 
Fig. 4. Western blot analysis of PRL-R expression in splenocytcs of 
rats from different ages. Splenocytes (2 x IO’) from 0, 2. 8. IO. 14. 
22. 30, 40, 50, 80. 90 day old rats were lysed in 200 jr1 lysis buffer and 
20 ~1 was subjected to Western blot analysis as in the legend to Fig. 
3. The membrane was stripped and relabeled with anti-actin mono- 
clonal antibodies at 2 pg/ml and incubated with sheep anti-mouse 
secondary antibodies. (A) Western blot. Lanes I -- I I correspond to 0, 
7 8, IO, 14. 22, 30, 40, 50, 80. and 90 daya. respectively. (B) 
;; uantification of Western blot. C. 42 kD band; n 84 kD band. Data 
represent average + S.E.M. of two rats. 
days; it declined again at 80 and 90 days. The develop- 
mental pattern of the expression of the 42 kD band was 
similar to that of the 84 kD band; during the first 10 
days after birth the level was relatively low. However, it 
increased significantly from days 10 to 50 and declined 
again in the older animals. At all the other ages tested 
(except for day 0 and 2) the relative level of the 42 kD 
band was greater than that of the 84 kD band. 
In contrast to splenocytes. only the 84 kD band was 
detected in thymocytes (Fig. 5(A)). Compared with the 
first 2 days, the level of the protein decreased from days 
10 through 90 (Fig. 5(B)). 
In addition to the antipeptide polyclonal antiserum 
against the long form of PRL-R, U6 mAb to the 
PRL-R was used in this study. First, we noted that 
38-40 kD proteins detected with U6 mAb were not 
recognized by antibodies to the long form of PRL-R 
(Fig. 6). The result is similar to that of Okamura et al. 
(1989a,b) and Dorato et al. (1992) who found that the 
U6 antibody recognizes a short form of PRL-R, 40 and 
42 kD. All the Western blots labeled with antibody to 
the long form of PRL-R were stripped and relabeled 
with U6 mAb to see how the level of the form detected 
by this antibody changed during development. In the 
-PRL-R 
-ACTIN 
180 - 
5 160- 
2 140 - 
CL - % 220 
5 IOO- 
5 -I 80- 
$ 60- 
g 40- 
8 20- 
B 
OL 
0 20 40 60 80 100 
Days After Birth 
Fig. 5. Western blot analysis of PRL-R expression in thymocytes of 
rats from different ages. Samples are exactly as described in the 
legend to Fig. 4 except hat thymocytes were used. (A) Western blot. 
Lanes I -11 correspond to 0. 2, 8, IO, 14, 22, 30, 40, 50. 80, and 90 
day old rats. respectively. (8) Quantification of Western blot. l , 84 
kD band. Data are the average f S.E.M. of two rats. 
spleen. the level of PRL-R detected with U6 mAb was 
relatively low during early days of neonatal life. 
Whereas the level doubled after day 14 and remained at 
about the same level until day 90, the last age tested 
(Fig. 6(A) and (B)). The developmental pattern of 
expression of the PRL-R short form was similar to that 
A I 2 3 4 5 6 7 8 9 IO 11 
,PFlL-A 
160 
‘is ioo 
5 
5 80 
-1 
2 60 
‘G 
3 40 
K 
20 I I I I I 
0 20 40 60 80 l&J 
Days After Birth 
Fig. 6. Western blot analysis of PRL-R expression in splenocytes 
detected with U6 mAb during diKerent ages. The membrane de- 
scribed in Fig. 4 was stripped and labeled with U6 mAb at I: 1000 
dilution. (A) Western blot. (B) Quantification of Western blot. 
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Fig. 7. PCR analysis of PRL-R short and long forms. Total RNA 
from splenocytes or thymocytes were reverse transcribed to cDNA 
and the resulting cDNA (10% of each cDNA reaction) was amplified 
by 40 cycles of PCR. After separation on an agarose gel. PCR 
products were transferred to an immobilon membrane and hybridized 
with biotinylated probes for the short and long forms of PRL-R. (A) 
Southern blot. Long form, 701 bp, lanes 1-3 (20, IO, 5 peg RNA, 
respectively); short form, 503 bp, lanes 4-6 (20, 10, 5 pg RNA 
respectively). (B) There was a linear relationship between the log of 
the chemiluminescent signal and the log of the RNA input. 
of the long form (Fig. 4). However, the abundance of 
the short form was always greater than that of long 
form during all the ages tested in spleen. 
In the thymus, the level of PRL-R detected with U6 
was relatively high at birth and did not show a consis- 
tent pattern of change throughout the periods tested 
(data not shown). 
3.3. The expression of long and short jbrms of PRL-R 
mRNA 
The levels of mRNA for the PRL-R were too low to 
be detected by Northern blots; thus, expression of 
mRNA was analyzed by RT-PCR. The long and short 
forms of PRL-R were detected in splenocytes and thy- 
mocytes of neonatal rats (Fig. 7(A)). The amplified 
product of the long and short forms were 701 and 593 
bp, respectively. A linear relationship between log RNA 
input and the intensity of the autoradiographic signal 
was observed up to 20 pug RNA for 40 cycles of the 
PCR reaction (Fig. 7(B)). Therefore, 10 pug RNA was 
used for analysis of both forms. The samples were also 
adjusted so that the same linear relationship was ob- 
tained for /3-actin, as an internal standard. 
The mRNA for the long form was detected in spleno- 
cytes from every age animal tested (Fig. 8(A) and (B)); 
the level increased by 1.5 to nearly 2-fold from birth to 
8 days of age and then remained at a steady level. The 
mRNA of the short form also was observed at all ages; 
but the mRNA levels at birth and day 2 were relatively 
low. After day 2, they increased. At all ages tested the 
relative levels of the long form were greater than that of 
+ACTlN 
0 Long F0m.1 
0 Short Form 
cc 0 5 10 15 20 25 30 
Days After Birth 
Fig. 8. The expression of PRL-R short and long form mRNA in rat 
splenocytes from different neonatal ages. Total RNA IO pg from 0, 2, 
IO, 14, 22, and 28 day old neonatal splenocytes were used to prepare 
PCR products as in the legend to Fig. 7. In addition to primers for 
short and long form, a primer for actin was included. (A) Southern 
blot of PCR products. Long form, lanes 2-8 are days 0, 2, 8, IO, 14, 
22, and 28, respectively); short form, lanes 9-15 are days 0, 2, 8, IO, 
14. 22, and 28, respectively). Lane I is a negative control without 
cDNA. (B) Quantification of Southern blot. The experiment was 
repeated with similar results. 
the short form (Table 1). However, after day 8, the 
difference between them became smaller. 
In thymic tissue the mRNA for the long form in- 
creased gradually until day 22 and remained at the 
same level at day 28 (Fig. 9(A) and (B)). The short 
form mRNA increased similarly. The levels of the long 
form of the mRNA were always greater than that of the 
short form mRNA (Table 1). On the other hand, the 
difference between the amounts of mRNA of two forms 
became less after day 10. 
Table I 
Comparison of PRL-R short and long form mRNA levels during 
different neonatal ages 
Days Ratio of long form to short form 
Splenocytes Thymocytes 
0 4.8 3.7 
2 7.6 4.2 
8 2.3 ND” 
IO I.4 3.4 
I4 1.0 2.2 
22 1.6 2.2 
28 1.2 1.8 
The relative amounts of the long and short forms of the PRL-R as 
detected by PCR analysis and after normalizing to actin were com- 
pared. 
“ND, not done. 
48 
A 12 3 45 6 79910111213 
CPRL-R 
tACTIN 
< 140 
E 
0 Long Form 
E 120 - 0 Short Form 
rr o----.-i 
0 5 10 15 20 25 30 
Days After Birth 
Fig. 9. The expression of PRL-R short and long form mRNA in rat 
thymocytes from different neonatal ages. Total RNAs (IO fig) from 0. 
2, 10, 14, 22, and 28 day old neonates were reverse transcribed to 
cDNA and analyzed with PCR as in the legend to Fig. 7. (A) 
Southern blot analysis. Samples were the same as in the legend to Fig. 
8 except day 8 was skipped. (B) Quantification of Southern blot. The 
experiment was repeated with similar results. 
3.4. EfSect of milk ingestion on PRL-R expression uncl 
mitogen responsiveness of l_vmphocytes 
Because previous studies from our laboratory had 
indicated that milk PRL deprivation in rat neonates 
altered the in vitro mitogen response as well as the 
expression of stage specific differentiation antigens of 
thymocytes and splenocytes, we asked how the inges- 
tion or deprivation of milk affected expression of PRL- 
R. Three groups of neonatal rats were analyzed; one 
was sacrificed immediately at birth; the second was 
allowed to suckle for 7 h; the third was deprived of 
milk for 7 h. Both cell surface PRL-R expression and 
mRNA levels were measured. 
As determined with flow cytometric analysis for three 
different experiments, the expression of PRL-R on 
splenocytes from neonates deprived of milk for the first 
7 h was 22.3 + 3.9% compared with 19 f 2.1% for 
those sacrificed immediately at birth (Fig. 10(A)). On 
the other hand, the expression of PRL-R of neonates 
that had suckled for 7 h dropped to 9 k 2.6%. In 
thymocytes, the percentage of cells expressing PRL-R 
was almost the same at birth (10 _t 1.5%) and after 7 
h without milk (8 ? 1.4%) (Fig. 10(B)). However, in 
milk-fed pups the percentage dropped to 3% (Fig. 
1 l(B)). 
PCR analysis indicated the presence of mRNA for 
both the short and long forms of PRL-R in splenocytes 
l_L * 
Age (hours) ’ 7 7 
Milk 
+ 
Fig. 10. The effect of milk ingestion on cell surface PRL-R expres- 
sion. Splenocytes (A) or thymocytes (B) from rats sacrificed at birth 
(0 h), suckled for 7 h (plus milk), or 7 h (minus milk) were stained 
and the percentage of PRL-R positive cells determined as described in 
Materials and methods. Data are the mean k S.E.M. of three 
different experiments. *P < 0.05 compared with 0 h and minus milk 
(Student’s t-test). 
and thymocytes of milk deprived rat pups. The data 
suggested that milk ingestion for the first 7 h did not 
aIfect the level of mRNA compared with birth (data 
not shown). 
Based on a previous study, splenocytes and thymo- 
cytes from neonatal rats deprived of milk PRL with 
2.5 
2.0 
1.5 
3 1.0 
5 0.5 
,E 240 
z 200 
.S 160 
cn 
120 
ConA 
Addition to Culture 
Fig. 1 I. The effect of milk ingestion on the response of splenocytes 
(A) or thymocytes (B) to mitogenic stimulation. Pups were fed with 
either day 1 milk or day 7 milk for 5 days and sacrificed. Splenocytes 
2.5 x 10h/ml or thymocytes 5 x 106/ml were incubated with ConA 
at I pgjml for 72 h and [‘H]TdR incorporation determined as 
described in the methods. Data presented are the mean + S.E.M. of 
two ditferent experiments. [3H]TdR incorporation of unstimulated 
splenocytes was 1422 CPM; and that of thymocytes was 573 CPM. 
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bromocriptine have an accelerated and increased re- 
sponse to mitogens as well as alterations in the percent- 
ages of thymocytes or splenocytes expressing cell 
surface markers (Grove et al., 1991). Cross-fostering 
was chosen as a way to deplete or decrease milk PRL 
level because the concentration of milk PRL changes 
during lactation. Pups from the same litter were divided 
into two groups. The first group (6 pups) was put with 
a mother at day 1 of lactation when milk PRL is high; 
whereas, the second group was placed with a foster 
mother at day 7 of lactation when milk PRL is low. 
Pups were allowed to suckle for 5 days and sacrificed. 
Splenoytes and thymocytes from both groups of pups 
were incubated in the presence or absence of ConA at 
1 fig/ml. [3H]TdR incorporation assay was performed 
to determine how the milk PRL concentration might 
affect the mitogen responsiveness of these neonatal 
lymphocytes. [‘H]TdR incorporation of splenocytes 
from pups fed with day 7 milk increased 1.2-fold com- 
pared with that of splenocytes from neonates fed with 
day 1 milk (Fig. 11(A)). Similarly, the ConA respon- 
siveness of thymocytes from pups fed with day 7 milk 
was higher (1.6-fold) than that of thymocytes from 
neonates fed with day 1 milk (Fig. 1 l(B)). These find- 
ings suggest hat either high concentration of PRL or 
certain PRL variants in early milk may inhibit 
lymphocyte proliferation in response to ConA or that 
later milk might contain stimulators. 
4. Discussion 
In this present study, we examined PRL-R expression 
in splenocytes and thymocytes of neonatal rats from 
birth to adulthood using a polyclonal or a monoclonal 
antibody. The antipeptide antibody to the long form of 
PRL-R detected two proteins, 84 kD and 42 kD, in 
splenocytes. 
One possibility is that the 42 kD protein in spleen is 
a degradation product of the 84 kD protein in spite of 
the fact that protease inhibitors were included during 
the cell lysis. However, the possibility seems unlikely 
because the 84 kD form was detected in the thymus and 
liver microsome preparations with the same antibody. 
Moreover, we never detected any intermediate sizes nor 
did the relative ratios of the 42 kD band to the 84 kD 
band change from time to time with the same sample 
preparation. Therefore, it is possible that the long form 
of the PRL-R may exist in two different isoforms in 
splenocytes due to different postranscriptional or pos- 
translational modifications. In support of this idea is 
the report that the cross-linking of [‘*‘I]ovine prolactin 
(oPRL) with PRL-R revealed several different molecu- 
lar forms (80, 50, 40, 16 kD) of PRL-R in mammary 
glands and in the liver (80, 40 kD) (Guillaumot and 
Cohen, 1994). Also, Hu and Dufau (1991) indicated 
that there were multiple forms of PRL-R mRNA as 
well as a variant form of PRL-R mRNA for the long 
form with a truncated and altered extracellular domain. 
During neonatal development the level of both the 42 
and 84 kD protein bands was low between birth and 
day 14, increased at day 22, and reached adult levels at 
day 30 (Figs. 3, 7(B)). Although both the 42 kD and 84 
kD PRL-R exhibited similar developmental patterns, 
the level of the 42 kD protein was always higher than 
that of the 84 kD one (Table 1). On the other hand, 
only the 84 kD PRL-R was detected in thymus using 
the same antibody. The relative level remained constant 
from birth to 90 days of age (Figs. 3, S(B)), suggesting 
that the long form of PRL-R detected with this anti- 
body is not developmentally regulated after birth in the 
thymus. These differential expression patterns of the 84 
kD PRL-R in spleen and thymus suggest hat regula- 
tion of PRL-R levels is tissue specific. Similarly, 
Hayden et al. (1979) found a negative correlation be- 
tween the number of PRL binding sites in the mam- 
mary gland and in the liver. They showed that the 
binding of ‘251-labeled oPRL to rat mammary gland 
microsomes decreased between 30 and 100 days of age; 
whereas, binding to liver microsome increased at these 
ages. 
The tissue specific expression of the 42 kD PRL-R 
implies that this PRL-R variant may have tissue specific 
functions. For example, thyroid hormone and retinoic 
acid have receptors that exist in several different iso- 
forms in different tissues with different biological func- 
tions (Hodin et al., 1989; Kastner et al., 1990; 
Mangelsdorf et al., 1990). Also, the existence of differ- 
ent isoforms of PRL (Grosvenor et al., 1992; Sinha, 
1995) suggests that each might exert different biological 
functions. Becuse the spleen unlike the thymus contains 
B cells and natural killer cells (NK), the 42 kD band 
might be cell specific. The function of each cell popula- 
tion differs from that of others. Therefore, it is possible 
that the 42 kD PRL-R could be required for exerting 
PRL’s effect on B and NK cells’ function rather than T 
cells’ function. The thymus contains mainly T cells and 
does not express the 42 kD PRL-R. 
Analysis of the PRL-R seen with the U6 mAb in the 
spleen during different ages revealed that relative level 
of this form correlated with development and exhibited 
a similar pattern of expression as the long form. The 
abundance of PRL-R protein detected with the U6 
antibody was greater than that of the long form protein 
at almost every age tested in both spleen and thymus. 
This finding suggests that the role of this form of 
PRL-R may be similar in both tissues. 
Developmental regulation of PRL-R expression also 
was examined in the liver by Jolicoeur et al. (1989) 
using Northern blot analysis and an [‘251]oPRL binding 
assay. Their results showed that PRL-R gene expres- 
sion is developmentally regulated at both transcrip- 
tional and translational levels in liver from fetal and 
newborn pups, i.e. the level of PRL-R mRNA and PRL 
binding sites increased as rats aged. Similar to their 
results, we also found that the amount of PRL-R 
mRNA increased as a function of age in both the 
spleen and the thymus. In addition, the level of PRL-R 
protein increased with age in the spleen but not in the 
thymus. The presence of PRL-R short and long form 
mRNA and protein as early as birth in the spleen and 
thymus, implies that both forms of PRL-R can bind 
and respond to PRL. 
Ontogeny of the thymus and spleen differ. The thy- 
mus is already mature at birth in regard to expression 
of cell surface differentiation markers (CD4, CD5, 
CDS. and Thy-l) and can respond to mitogens (Ritter 
et al., 1987; Middleton and Bullock, 1984; Grove et al.. 
1991). In addition, PRL-Rs have been detected in fetal 
rat thymus (Freemark et al., 1995; Royster et al., 1995). 
Likewise, this present study showed that the expression 
of PRL-R protein in the thymus at birth was also at 
adult levels. These findings suggest that the expression 
of the PRL-R gene is regulated along with those con- 
trolling T-cell differentiation during gestation in the 
thymus. PRL-R expression during gestation implies 
that PRL has a function on the early development of 
T-cells. The presence of PRL-R in thymocytes as well 
as the fact that PRL decreases thymic cellularity in 
dwarf mice (Murphy et al., 1993) suggest that PRL 
plays a role in education and selection of T-cells in the 
thymus. In contrast, PRL stimulates proliferation of 
mature T-cells in peripheral blood and lymph nodes 
(Gala and Shevach, 1993; Murphy et al., 1993). 
In contrast to the thymus, the spleen is an immature 
organ at birth. NK activity, the level of cell surface 
markers and mitogen responsiveness are absent or are 
very low at birth (Vujanovic et al., 1988; Grove et al., 
1991; Middleton and Bullock, 1984). Although T and B 
cells have been observed at birth (Dijkstra and Dopp, 
1983). the percentage of cells expressing B cell marker 
(Ig) and T cell markers (CD4, CD5, CD8 and CD2) 
increased with age and reached adult levels by day 15 of 
neonatal life (Grove et al., 1991). Similarly, we found 
that the level of PRL-R in the spleen was relatively low 
at birth and increased with age. One possibility is that 
the increase in the percentage of PRL-R positive cells 
during development is due to the migration of T and B 
cells to the spleen. The microenvironment of lymphoid 
tissue as well as type of cell population may account for 
differences in the level of PRL-R expression in spleno- 
cytes and thymocytes. 
The finding that both PRL-R short form and long 
form mRNA were expressed in the spleen and thymus 
of neonatal rats is consistent with the results of Ouhtit 
et al. (1993) who demonstrated short and long form 
PRL-R mRNA expression in the spleen and thymus 
using in situ hybridization techniques. Like Ouhtit et al. 
(1993) we also found that the level of the transcript 
was higher for the long form than the short form in 
both tissues. However, at this time neither our study 
nor the studies of others allow us to state whether each 
individual cell expresses both long and the short forms 
of the receptor. PCR analysis of RNA from a single cell 
would answer this question. 
As described in the experimental procedure (Fig. 1). 
the cDNA sequence of primers for PCR analysis and 
amino acid sequences for antibody production were 
chosen from non-homologous sequences to differentiate 
the short and long forms of PRL-R at mRNA and 
protein levels. However. the long form sequence used 
for antibody production is different from the one used 
for PCR analysis, i.e. these sequences are hundred base 
pairs apart. Therefore, if there is an isoform of PRL-R 
long form, truncated at the cytoplasmic region which 
excludes the primer sequences for PCR analysis of the 
long form, this isoform of the receptor would not have 
been amplified with PCR. When the relative levels of 
PRL-R long form of mRNA in the spleen were com- 
pared to that of the PRL-R proteins in the same tissue 
during different ages, it was found that PRL-R long 
form mRNA changed only during birth and day 2 but 
remained at a steady level at the other ages tested. 
However, PRL-R protein increased from birth to 28 
days of age. i.e. the protein level gradually increased as 
rats got older. These results show that the protein level 
did not exactly parallel the mRNA levels. They suggest 
that gene expression of PRL-R long form might be 
regulated at the translational level in spleen. 
In the case of the thymus. an increase in both the 
PRL-R short and long form mRNA’s from birth to 28 
days of age indicated that gene expression changed with 
development at the transcriptional level. As in the 
spleen, the levels of PRL-R long form protein during 
all the ages tested did not correlate with the level of 
long form mRNA in the thymus. This result suggests 
that the long form of PRL-R expression is probably 
regulated at the translational level in the thymus. 
During fetal life, the major source of PRL is the 
placenta. Milk-borne and pituitary PRL serve as post- 
natal sources of PRL for neonates. Milk-borne PRL 
enters the neonatal circulation within 30-40 min after 
suckling begins (Whitworth and Grosvenor, 1978). 
Therefore, PRL-R expression at the mRNA and 
protein levels was examined after milk ingestion in this 
study. The results show that lack of milk in the first 7 
h did not change the percentage of cells expressing 
surface PRL-R compared to that at birth. However, 
ingestion of milk in the first 7 h decreased the percent- 
age of PRL-R positive cells (Fig. 10). This decrease 
may reflect the down-regulation of the PRL-R after 
PRL binding and internalization of hormone-receptor 
complex. This finding is consistent with the results of 
Djiane et al. ( 1979) who showed the rapid down-regula- 
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tion of the receptor in mammary gland at high concen- 
trations of PRL. This down-regulation of PRL-R ex- 
pression after milk ingestion indicates that milk-borne 
PRL functions directly on lymphocytes. The fact that 
the level of mRNA for PRL-R was largely unaffected 
after milk ingestion supports a direct action of PRL on 
the receptor. 
After ConA stimulation, DNA synthesis of spleno- 
cytes and thymocytes from rats fed with day 7 milk was 
higher than that of splenocytes and thymocytes fed with 
day 1 milk. These results suggest that a certain PRL 
variant in early milk could have an inhibitory effect on 
lymphocyte proliferation. In fact, the glycosylated frac- 
tion of human milk has been reported to be inhibitory 
to Nb2 cells (Ellis and Picciano, 1995). According to 
Grosvenor et al. (1992) the concentration and type of 
PRL variants change during the course of lactation. In 
addition, the fact that there are neonatal splenocytes 
adherent suppresser cells (Middleton and Bullock, 
1984) and weaning decreased the suppresser activity 
suggest a connection between PRL and suppressive 
activity of adherent cells. Therefore, much more exten- 
sive work is necessary to determine which stage of 
lactation or which PRL variants are the most effective 
in altering immune cell function. 
In summary, splenocytes and thymocytes expressed 
cell surface PRL-Rs from birth through adulthood, 
These results suggest that PRL plays some role in the 
development of the neonatal immune system. However, 
the variants in the forms of PRL-R seen in the thymus 
and spleen suggest a tissue or cellular basis for a 
differential response to PRL. Moreover, levels of 
mRNA and protein for both the short and long form 
do not parallel each other during different neonatal 
ages. Therefore, it can be concluded that expression of 
PRL-R long and short form is regulated at the transla- 
tional level in both the spleen and thymus. Finally, the 
milk ingestion in the first 7 h of life decreased the 
percentage of both splenocytes and thymocytes express- 
ing cell surface PRL-R, suggesting that milk-borne 
PRL may have a direct effect on lymphocytes. 
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